ID: ALA5193666

Max Phase: Preclinical

Molecular Formula: C23H25ClN2O3S

Molecular Weight: 444.98

Associated Items:

Representations

Canonical SMILES:  Cc1cc(CC(=O)O)cc(OCCC2CCN(c3nc4ccc(Cl)cc4s3)CC2)c1

Standard InChI:  InChI=1S/C23H25ClN2O3S/c1-15-10-17(13-22(27)28)12-19(11-15)29-9-6-16-4-7-26(8-5-16)23-25-20-3-2-18(24)14-21(20)30-23/h2-3,10-12,14,16H,4-9,13H2,1H3,(H,27,28)

Standard InChI Key:  ZPVDMEPVFBETQM-UHFFFAOYSA-N

Associated Targets(Human)

PPARA Tclin Peroxisome proliferator-activated receptor alpha (9197 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PPARG Tclin Peroxisome proliferator-activated receptor gamma (15191 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PPARD Tchem Peroxisome proliferator-activated receptor delta (6293 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Ppard Peroxisome proliferator-activated receptor delta (358 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 444.98Molecular Weight (Monoisotopic): 444.1274AlogP: 5.57#Rotatable Bonds: 7
Polar Surface Area: 62.66Molecular Species: ACIDHBA: 5HBD: 1
#RO5 Violations: 1HBA (Lipinski): 5HBD (Lipinski): 1#RO5 Violations (Lipinski): 1
CX Acidic pKa: 4.16CX Basic pKa: 2.47CX LogP: 6.00CX LogD: 3.08
Aromatic Rings: 3Heavy Atoms: 30QED Weighted: 0.52Np Likeness Score: -1.57

References

1. Kato T, Ohara T, Suzuki N, Muto S, Tokuyama R, Mizutani M, Fukasawa H, Matsumura KI, Itai A..  (2022)  Discovery and structure-based design of a new series of potent and selective PPARδ agonists utilizing a virtual screening method.,  59  [PMID:35063634] [10.1016/j.bmcl.2022.128567]

Source